Navigation Links
New Data Show That Herceptin, Xeloda and Avastin Help Patients With Early and Advanced Breast Cancer Live Longer or Remain Disease Free for Longer
Date:12/10/2008

ves of women with advanced breast cancer.

"Researching new cancer treatments is a complex step by step process. Each success helps lay the foundation for the next step forward," said William M. Burns, CEO Division Roche Pharmaceuticals. "These results show that we are making significant progress towards giving doctors and their breast cancer

patients better and more effective treatment options to fight this devastating disease at all stages," he added.

    Presentation of Data

    Herceptin

    Gianni L et al  Neoadjuvant trastuzumab in patients with   Friday 12th,
                    HER2-positive locally advanced breast      December
                    cancer: primary efficacy analysis of the   09:30 hrs
                    NOAH trial                                 General
                                                               Session 3
                                                               (Hall D)

    Xeloda

    Joensuu H et    Significant improvement in                 Sunday 14th,
    al. for The     recurrence-free survival (RFS)             December
    Finnish Breast  when capecitabine (X) is                   11:45 hrs
    Cancer Group    integrated into docetaxel (T)              General
                    5-FU + epirubicin + cyclophosphamide       Session 7
                    (CEF) adjuvant therapy for high-risk
                    early breast cancer (BC): interim
                    analysis of the FinXX-trial.

    Avastin

    Smith IE et al  Primary analysis of study MO19391, an      Saturday
                    open-label safety study of bevacizumab     13th,
                    plus taxane-based therapy as 1st-line      December
                    treatment of patients with locally         07:00 hrs
                    recurrent or metastatic breast cancer.     Poster
                                                               Session 4

'/>"/>
SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
2. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
3. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
4. Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
5. Over 30 New Studies of Oral Xeloda(R) Featured at the 2008 Gastrointestinal Cancers Symposium
6. Novel Xeloda(R) Dosing Schedule May Offer Well-Tolerated Alternative for Treatment of Advanced Breast Cancer
7. Nearly 60 New Studies of Oral Xeloda(R) (capecitabine) Featured at the 44th American Society of Clinical Oncology Annual Meeting
8. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
9. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
10. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
11. Pilot Study Opens the Door for Avastin Use in Curative Setting for Women With Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 18, 2014  KIYATEC announced today that it ... Innovation Research (SBIR) Phase II Contract from the ... institutes and centers that comprise the National Institutes ... two year award, KIYATEC will expand its 3D ... the forefront of cancer therapy strategies: 1) cancer,s ...
(Date:9/18/2014)... 18, 2014  Decision Resources Group finds that Regeneron,s ... (VEGF) agent for wet AMD, is equally likely to ... Genentech,s Lucentis, which is the standard of care for ... (MCO) directors do not identify a clear clinical or ... than Lucentis to be listed on tier 1 or ...
(Date:9/18/2014)... MEETING, Pa. , Sept. 18, 2014 ... trial solutions, was recognized as the Disruptive ... for its ePharmaONE cloud-based eClinical platform. This ... and electronic trial master file (eTMF), a ... solution, and ePharmaSolutions, ReferralPlus+ patient screening and ...
Breaking Medicine Technology:National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 2National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 3Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 2Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 3ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 2ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 3
... OF ELAGOLIX ON BONE MINERAL DENSITY, SAN DIEGO, ... announced today that the elagolix 0603 Phase IIb trial,(Petal ... subject,completed her Week 24 study visit in early June. ... on bone mineral density (BMD) as,the primary endpoint using ...
... Prevention and Control Professionals Cite,Greatest Needs for ... More Environmental Services and Time-Saving High Tech ... than three out of four,(76%) infection prevention ... implemented additional measures to prevent the,transmission of ...
Cached Medicine Technology:Neurocrine Biosciences Completes 'Petal Study' Treatment Phase for Endometriosis 2Neurocrine Biosciences Completes 'Petal Study' Treatment Phase for Endometriosis 3Nationwide Progress Poll Reveals Increased Efforts by Hospitals to Control MRSA Infection 2Nationwide Progress Poll Reveals Increased Efforts by Hospitals to Control MRSA Infection 3
(Date:9/18/2014)... German . ... the ,International Space Station Research Competition, with their project ... scientists will see the International Space Station crew perform ... two proteins of the hepatitis C virus under microgravity ... Space Station is scheduled to lift off from Cape ...
(Date:9/18/2014)... 2014 According to a new market report ... - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, ... was valued at USD 77607.7 million in 2013 and is ... to 2020, to reach an estimated value of USD 115474.9 ... market is growing at a rapid pace due to increasing ...
(Date:9/18/2014)... September 18, 2014 “Awesome” is the ... (Smart Teens Accepting Responsibility Today) Internship Program at ARDX ... Darcy C. describe the program as “Inspirational” and “Life-changing,” ... idea about what they would be doing during their ... do food runs and other mindless tasks,” but, instead ...
(Date:9/18/2014)... HealthDay Reporter WEDNESDAY, ... may be associated with increased odds of developing Parkinson,s ... research suggests. The study, which did not prove ... suggested that the migraine-Parkinson,s association was stronger in women ... warning sign of a pending attack that includes flashes ...
(Date:9/18/2014)... 2014 How much is a serving? ... the factors contributing to the obesity epidemic in the ... serving and how to manage portion size during the ... 3 at Humility House, 755 Ohltown Road, Austintown. , ... the informational discussion and answer questions from 12:30 to ...
Breaking Medicine News(10 mins):Health News:Hepatitis C virus proteins in space 2Health News:Dialysis Products and Services Market Expected to Reach USD 115.4 Billion Globally in 2020 2Health News:Dialysis Products and Services Market Expected to Reach USD 115.4 Billion Globally in 2020 3Health News:Dialysis Products and Services Market Expected to Reach USD 115.4 Billion Globally in 2020 4Health News:ARDX Internship Helps Students to START on the Right Business Path 2Health News:ARDX Internship Helps Students to START on the Right Business Path 3Health News:ARDX Internship Helps Students to START on the Right Business Path 4Health News:Are Migraines in Middle Age Tied to Raised Parkinson's Risk Later? 2Health News:Are Migraines in Middle Age Tied to Raised Parkinson's Risk Later? 3Health News:HMHP Workshop Addresses Portion Control 2
... and poultry products from Taiwan, Hong Kong, and four ... to 17.//,The step has come as a precaution against ... ,Last month, Pakistan put a similar ban on ... Indonesia, Cambodia, Laos, Russia, Kazakhstan, Mongolia, Turkey, Greece and ...
... is a major factor increasing the cholesterol level in ... by the body in moderate amounts, can lead to ... Lena Brydon of University College London examined 199 healthy ... to stress and whether their reaction can increase cholesterol ...
... bird flu, even as the government has given approval to ... ,The latest outbreaks of the deadly H5N1 strain of the ... province of Yunnan and the northwestern region of Ningxia, the ... died in Yunnan's Chuxiong district Thursday, and 230 died in ...
... of its super-speciality hospital chain with a 280-bed hospital ... ,"We have embarked on the construction of a ... be ready by 2007-end. We also plan Greenfield projects ... president, told IANS., ,Unlike the existing 110-bed cardiac ...
... of more than 1,200 children, whose organs were removed after ... an average of about ?2,900 in a compensation deal announced ... is the apex body had fought the cases involving ... ago to a total figure of around ?3.6 million for ...
... could be putting their health at risk by failing ... other health professionals.// ,The survey of more than ... Professions Council (HPC), found that about 81% of people ... were oblivious to whether they were properly qualified to ...
Cached Medicine News:Health News:Wockhardt Group Plans Hospital In Delhi By End-2007 2Health News:Organ Scandals Compensation And The Aftermath 2Health News:Credentials Of Specialists Need To Be Checked 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: